LAG3 immune inhibitors: a novel strategy for melanoma treatment

Renzheng Wu; Mingtang Zeng; Yuchen Zhang; Jianping He

doi:10.3389/fonc.2024.1514578

LAG3 immune inhibitors: a novel strategy for melanoma treatment

Front Oncol. 2024 Dec 18:14:1514578. doi: 10.3389/fonc.2024.1514578. eCollection 2024.

Authors

Renzheng Wu¹, Mingtang Zeng¹, Yuchen Zhang¹, Jianping He²

Affiliations

¹ Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China.
² Division of Abdominal Tumor Multimodality Treatment, Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Melanoma, a highly aggressive skin cancer, poses significant challenges in treatment, particularly for advanced or metastatic cases. While immunotherapy, especially immune checkpoint inhibitors (ICIs) targeting CTLA-4 and PD-1, has transformed melanoma management, many patients experience limited responses or develop resistance, highlighting the need for new therapeutic strategies. Lymphocyte activation gene 3 (LAG-3) has emerged as a promising target in cancer immunotherapy. LAG-3 inhibitors have shown potential in restoring T cell functions and enhancing anti-tumor immunity, particularly when used in combination with existing ICIs. This review discusses the latest advancements in LAG-3 inhibition for advanced melanoma, emphasizing its role in overcoming resistance and improving patient outcomes.

Keywords: antitumor immunity; clinical trial; immune checkpoint inhibitors; lymphocyte activation gene 3; melanoma.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by National Key Clinical Specialties Construction Program.